Mark Anderson

On Friday, the FDA gave the nod to Janssen Pharmaceutical’s combination of niraparib and abiraterone acetate, branded as Akeega, designed to treat metastatic castration-resistant prostate cancer in patients with the BRCA mutation. Janssen, a branch of Johnson & Johnson, revealed that Akeega is the inaugural dual-function tablet fusing the capabilities of a PARP inhibitor and […]

The FDA has postponed its decision on Valneva’s chikungunya vaccine candidate, VLA1553, moving the PDUFA action date to the end of November, as confirmed by Valneva on Monday. The initial decision was scheduled for the end of August. This extension was granted to provide ample time to harmonize and finalize a phase 4 trial, essential […]